Navigation Links
GEN reports on the greening of the life sciences
Date:9/2/2010

New Rochelle, NY, September 1, 2010Biopharmaceutical firms and other life science organizations are taking definitive steps toward creating greener working environments and developing more sustainable operations, reports Genetic Engineering & Biotechnology News (GEN). This promising trend was made clear through a series of presentations and panel discussions that took place at GEN's (www.genengnews.com/gen-articles/biopharma-s-going-green/3381), "GreenBioPharma" conference, which was recently held in Philadelphia.

"The main message that emerged from our meeting was that going green is not only beneficial to the environment but that sustainable practices make good economic sense as well," said John Sterling, Editor in Chief of GEN.

Topics ranged from environmentally sensitive building design, air-quality monitoring systems, automation, energy efficiency, water-reduction strategies, biocatalysis to optimize process dynamics, and waste reduction and recycling. Many of the presentations emphasized the operational efficiencies and sustainable advantages of switching to disposable technologies across the process stream, including savings in labor, energy, water, chemical use, and overall costs.

Beth Junker, Ph.D., senior scientific director in bioprocess R&D at Merck, encouraged companies to assess the environmental footprints of their chemical processessuch as the aquatic toxicity of heavy metalsearly in the product life cycle. Dr. Junker identified three main opportunities for waste (including energy) reduction: process intensification, easing of purification bottlenecks, and a shift in focus in purification from product capture to contaminant removal.

A case study describing fermentation processes at Bayer Healthcare's Berkeley, CA, site, where Bayer's factor VIII is produced, identified "quick wins" in utility use reduction, followed by process changes using technology to increase efficiency and reduce cost-of-goods. These included increasing the height of chromatography columns (but staying within established process specifications to avoid the need for re-evaluation), which is predicted to increase yield by 5%, saving millions of dollars and reducing the carbon footprint of this unit operation by about 3%.

Life Technologies' internal energy-efficiency efforts are expected to save the company a projected $25 million between 2004 and 2012. Cristina Amorim, vp of global EHS and citizenship, told conference attendees that big savings can come from unexpected places. For example, historically Life Technologies had shipped its Applied Biosystems TaqMan assays to customers in Styrofoam coolers. Looking for ways to reduce waste, the company performed stability tests and determined that the reagents could safely be shipped in regular packaging, eliminating the use of 100,000 coolers per year and saving the company $1.5 million/year.

Included among the other speakers at GEN's GreenBioPharma were representatives from GE Healthcare, Sartorius Stedim Biotech, Genentech, University of Pennsylvania, Intelligen, Ohio State University, Millipore, Diamond & Schmitt Architects, Clayco, Waters, Agilent Technologies, SciQuest, University of Maryland, Integrated Project Services, Hyde Engineering, RC Bio/Ingenza, and the University of Maryland.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Aware, Inc. Reports Second Quarter 2010 Financial Results
2. GEN reports on rediscovered technology to bolster proteomics research
3. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
4. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
5. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
6. New climate change reports underscore need for action
7. BIO-key(R) Reports First Quarter 2010 Financial Results
8. Survey reports latest honey bee losses
9. Grupo Radio Centro Reports First Quarter 2010 Results
10. Primary Energy Reports Improved First Quarter Results
11. GEN reports on the promise of DNA vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GEN reports on the greening of the life sciences
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: